Loading clinical trials...
Loading clinical trials...
A 12 Months, Prospective, Multicenter, Open-label, Single Arm Interventional Study Assessing the Safety and Tolerability of 0.5 mg Ranibizumab in Mono/Bilateral Wet AMD Patients in Eyes With (Best-Corrected Distance Visual Acuity) BCVA Below 2/10 and/or Second Affected Eye
Conditions
Interventions
ranibizumab
Locations
101
Italy
Novartis Investigative Site
Alessandria, AL, Italy
Novartis Investigative Site
Casale Monferrato, AL, Italy
Novartis Investigative Site
Ancona, AN, Italy
Novartis Investigative Site
Acquaviva delle Fonti, BA, Italy
Novartis Investigative Site
Putignano, BA, Italy
Novartis Investigative Site
Terlizzi, BA, Italy
Start Date
March 4, 2014
Primary Completion Date
June 15, 2016
Completion Date
June 15, 2016
Last Updated
July 19, 2019
NCT06704009
NCT06668064
NCT06683742
NCT07255885
NCT06969001
NCT05562336
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions